BioSyent (CVE:RX) Hits New 52-Week High – Should You Buy?

BioSyent Inc. (CVE:RX)’s stock price reached a new 52-week high on Tuesday . The company traded as high as C$14.93 and last traded at C$14.90, with a volume of 2711 shares. The stock had previously closed at C$14.93.

Analysts Set New Price Targets

Separately, Bloom Burton upgraded shares of BioSyent from a “moderate buy” rating to a “strong-buy” rating in a research report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

BioSyent Stock Up 1.8%

The stock has a market capitalization of C$169.62 million, a price-to-earnings ratio of 20.13 and a beta of 0.52. The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90. The business’s 50-day moving average is C$13.11 and its two-hundred day moving average is C$12.06.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.